GNLX

GeneluxA

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$6.50

Analysis reference price unavailable

Analysis 2026-09-04 · RankAlpha Sentiment Codex

Most likely

Base case

50%

Probability

Target price

$3.20

Analysis reference price unavailable

Analysis 2026-09-04 · RankAlpha Sentiment Codex

B-

Bear case

25%

Probability

Target price

$1.10

Analysis reference price unavailable

Analysis 2026-09-04 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-09-04

AI commentary

The latest company investor-relations release is constructive on clinical progress and upcoming readouts, but its forward-looking statements remain binary and execution-dependent. The packet contains no recent-news feed, social coverage, options data, short-interest data, employee rating, analyst revisions, or verified post-print price reaction; missing reaction and revision data are not treated as positive evidence.

RankAlpha Sentiment Codex - 2026-09-04

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-12-03eventPhase 3 OnPrime/GOG-3076 topline dataHigh impact

The company expects topline data from its randomized Phase 3 registrational ovarian-cancer trial in the second half of 2026. Favorable efficacy and safety could materially re-rate the stock, while a miss or safety signal would create substantial downside. [#PR-EARNINGS-2026-08-13](https://investors.genelux.com/news-releases/news-release-details/genelux-corporation-reports-second-quarter-financial-results-and)

2026-12-03catalystCash-runway and financing overhangHigh impact

The company reported $18.7 million of cash, equivalents, marketable securities and restricted cash at June 30, 2026, expected to fund operations into the first quarter of 2027. With no reported revenue and continued clinical spending, future financing or dilution remains a material overhang. [#PR-EARNINGS-2026-08-13](https://investors.genelux.com/news-releases/news-release-details/genelux-corporation-reports-second-quarter-financial-results-and)

2027-09-04catalystSystemic Olvi-Vec lung-cancer dose updatesHigh impact

Additional dose-finding updates from the SCLC and NSCLC programs are expected in 2026 and may inform systemic dosing and future registrational development. [#PR-EARNINGS-2026-08-13](https://investors.genelux.com/news-releases/news-release-details/genelux-corporation-reports-second-quarter-financial-results-and)

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-09-04 • Updated nightlySource: Internal modelMethodology